Monoclonal antibody · Antagonist of respiratory syncytial virus F protein · developed by Merck Sharp Dohme
Clesrovimab (ENFLONSIA) is a monoclonal antibody that binds the respiratory syncytial virus (RSV) F protein and inhibits viral fusion. It is studied in RSV infection, including prevention of RSV lower respiratory tract disease in neonates and infants.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Oct 14, 2026). Read the full label for the exact wording, limitations and safety information.
RSV Infection
Updated Nov 15, 2026. Something wrong or missing? Report it on the MRK page.
See MRK's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
MRK catalysts and pipeline →